Use of botulinum toxins in cancer therapy

Bibliography

• ANSIAUX R, BAUDELET C, CRON GO et al.: Botulinum toxin potentiates cancer radiotherapy and chemotherapy. Clin. Cancer Res. (2006) 12(4):1276-1283.
   PubMed Web of Science ®Google Scholar
• ROSSETTO O, CACCIN P, RIGONI M, SEVESO M, TONELLO F, MONTECUCCO C: The metalloprotease activity of tetanus and botulinum neurotoxins. In: Scientific and therapeutic aspects of botulinum toxin. Brin MF, Jankovic J, Hallett M (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2002):3-10.
   Google Scholar
• HANSON MA, STEVENS RC: Structural view of botulinum neurotoxin in numerous functional states. In: Scientific and therapeutic aspects of botulinum toxin. Brin MF, Jankovic J, Hallett M (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2002):11-27.
   Google Scholar
• JOHNSON EA, BRADSHAW M: Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon (2001) 39(11):1703-1722.
   PubMed Web of Science ®Google Scholar
• DRESSLER D, ADIB SABERI F, REIS BARBOSA E: Botulinum toxin – mechanism of action. Arq. Neuropsiquiatr. (2005) 63(1):180-185.
   PubMed Web of Science ®Google Scholar
• PANICKER JN, MUTHANE UB: Botulinum toxins: pharmacology and its current therapeutic evidence for use. Neurol. India (2003) 51(4):455-460.
   PubMed Web of Science ®Google Scholar
• JOHNSON EA: Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Ann. Rev. Microbiol. (1999) 53:551-575.
   PubMed Web of Science ®Google Scholar
• MAHANT N, CLOUSTON PD, LORENTZ IT: The current use of botulinum toxin. J. Clin. Neurosci. (2000) 7(5):389-394.
   PubMed Web of Science ®Google Scholar
• HUANG W, FOSTER JA, ROGACHEFSKY AS: Pharmacology of botulinum toxin. J. Am. Acad. Dermatol. (2000) 43(2 Part 1):249-259.
   PubMed Web of Science ®Google Scholar
• DASGUPTA BR, SATHYAMOORTHY V: Purification and amino acid composition of type A botulinum neurotoxin. Toxicon (1984) 22(3):415-424.
   PubMed Web of Science ®Google Scholar
• DASGUPTA BR, SUGIYAMA H: Molecular forms of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect. Immun. (1976) 14(3):680-686.
   PubMed Web of Science ®Google Scholar
• SCHIAVO G, MATTEOLI M, MONTECUCCO C: Neurotoxins affecting neuroexocytosis. Physiol. Rev. (2000) 80(2):717-766.
   PubMed Web of Science ®Google Scholar
• AOKI KR, GUYER B: Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur. J. Neurol. (2001) 8(Suppl. 5):21-29.
   PubMed Web of Science ®Google Scholar
• SIMPSON LL: Identification of the major steps in botulinum toxin action. Ann. Rev. Pharmacol. Toxicol. (2004) 44:167-193.
   PubMed Web of Science ®Google Scholar
• LACY DB, TEPP W, COHEN AC, DASGUPTA BR, STEVENS RC: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. (1998) 5(10):898-902.
   PubMedGoogle Scholar
• SWAMINATHAN S, ESWARAMOORTHY S: Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. (2000) 7(8):693-699.
   PubMedGoogle Scholar
• DE PAIVA A, DOLLY JO: Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes. FEBS Lett. (1990) 277(1-2):171-174.
   PubMed Web of Science ®Google Scholar
• DE PAIVA A, ASHTON AC, FORAN P, SCHIAVO G, MONTECUCCO C, DOLLY JO: Botulinum A like type B and tetanus toxins fulfils criteria for being a zinc-dependent protease. J. Neurochem. (1993) 61(6):2338-2341.
   PubMed Web of Science ®Google Scholar
• RACIBORSKA DA, TRIMBLE WS, CHARLTON MP: Presynaptic protein interactions in vivo: evidence from botulinum A, C, D and E action at frog neuromuscular junction. Eur. J. Neurosci. (1998) 10(8):2617-2628.
   PubMed Web of Science ®Google Scholar
• KALANDAKANOND S, COFFIELD JA: Cleavage of intracellular substrates of botulinum toxins A, C, and D in a mammalian target tissue. J. Pharmacol. Exp. Ther. (2001) 296(3):749-755.
   PubMed Web of Science ®Google Scholar
• DOLLY JO, LISK G, FORAN PG et al.: Insights into the extended duration of neuroparalysis by botulinum neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In: Scientific and therapeutic aspects of botulinum toxin. Brin MF, Jankovic J, Hallett M (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2002):91-102.
   Google Scholar
• CHEN F, KUZIEMKO GM, AMERSDORFER P, WONG C, MARKS JD, STEVENS RC: Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect. Immun. (1997) 65(5):1626-1630.
   PubMed Web of Science ®Google Scholar
• DOLLY JO, DE PAIVA A, FORAN P et al.: Probing the process of transmitter release with botulinum and tetanus neurotoxins. Semin. Neurosci. (1994) 6(3):149-158.
   Google Scholar
• ASHTON AC, DE PAIVA AM, POULAIN B et al.: Factors underlying the characteristic inhibition of the neural release of transmitters by tetanus and various botulinum toxins. In: Botulinum and tetanus neurotoxins: neurottransmission and biomedical aspects. Das Gupta BR (Ed.), Plenum Publishing, New York, USA (1993):191-213.
   Google Scholar
• DOLLY JO, BLACK J, WILLIAMS RS, MELLING J: Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature (1984) 307(5950):457-460.
   PubMed Web of Science ®Google Scholar
• BLACK JD, DOLLY JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J. Cell Biol. (1986) 103(2):521-534.
   PubMed Web of Science ®Google Scholar
• DONG M, RICHARDS DA, GOODNOUGH MC, TEPP WH, JOHNSON EA, CHAPMAN ER: Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. (2003) 162(7):1293-303.
   PubMed Web of Science ®Google Scholar
• RUMMEL A, MAHRHOLD S, BIGALKE H, BINZ T: The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. (2004) 51(3):631-643.
   PubMed Web of Science ®Google Scholar
• DONG M, YEH F, TEPP WH et al.: SV2 is the protein receptor for botulinum neurotoxin A. Science (2006) 312(5773):592-596.
   PubMed Web of Science ®Google Scholar
• MAHRHOLD S, RUMMEL A, BIGALKE H, DAVLETOV B, BINZ T: The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. (2006) 580(8):2011-2014.
   PubMed Web of Science ®Google Scholar
• SIMPSON LL, DASGUPTA BR: Botulinum neurotoxin type E: studies on mechanism of action and on structure–activity relationships. J. Pharmacol. Exp. Ther. (1983) 224(1):135-140.
   PubMed Web of Science ®Google Scholar
• BLACK JD, DOLLY JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J. Cell Biol. (1986) 103(2):535-544.
   PubMed Web of Science ®Google Scholar
• FORAN PG, MOHAMMED N, LISK GO et al.: Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. (2003) 278(2):1363-1371.
   PubMed Web of Science ®Google Scholar
• MONTECUCCO C, MOLGO J: Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. (2005) 5(3):274-279.
   PubMed Web of Science ®Google Scholar
• JUZANS P, COMELLA JX, MOLGO J, FAILLE L, ANGAUT-PETIT D: Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromuscul. Disord. (1996) 6(3):177-185.
   PubMed Web of Science ®Google Scholar
• DE PAIVA A, MEUNIER FA, MOLGO J, AOKI KR, DOLLY JO: Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA (1999) 96(6):3200-3205.
   PubMed Web of Science ®Google Scholar
• AOKI K R: A comparison of the safety margins of botulinum neurotoxin serotypes A, B and F in mice. Toxicon (2001) 39(12):1815-1820.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERGH PY, LISON DF: Dose standardization of botulinum toxin. Adv. Neurol. (1998) 78:231-235.
   PubMedGoogle Scholar
• ODERGREN T, HJALTASON H, KAAKKOLA S et al.: A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry (1998) 64(1):6-12.
   PubMed Web of Science ®Google Scholar
• SAMPAIO C, FERREIRA JJ, SIMOES F et al.: DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1. Mov. Disord. (1997) 12(6):1013-1018.
   PubMed Web of Science ®Google Scholar
• TANG-LIU DDS, AOKI KR, DOLLY JO et al.: Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon (2003) 42(5):461-469.
   PubMed Web of Science ®Google Scholar
• HSU TSJ, DOVER JS, ARNDT KA: Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch. Dermatol. (2004) 140(11):1351-1354.
   PubMed Web of Science ®Google Scholar
• SCOTT AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology (1980) 87(10):1044-1049.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, BRIN MF: Therapeutic uses of botulinum toxin. N. Engl. J. Med. (1991) 324(17):1186-1194.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, BRIN MF: Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. (1997) 6:S129-S145.
   PubMedGoogle Scholar
• SCOTT AB, MAURIELLO JA, BLITZER A et al.: V Clinical Therapy. In: Scientific and therapeutic aspects of botulinum toxin. Brin MF, Jankovic J, Hallett M (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2002):3-10.
   Google Scholar
• CARRUTHERS A: Botulinum toxin type A: history and current cosmetic use in the upper face. Dis. Mon. (2002) 48(5):299-322.
   PubMed Web of Science ®Google Scholar
• GUO Y, SHIN K: Unique use of botulinum toxin to decrease adductor tone and allow surgical excision of vulvar carcinoma. Int. J. Gynecol. Cancer (2004) 14(1):100-103.
   PubMed Web of Science ®Google Scholar
• LOU JS, PLENINGER P, KURLAN R: Botulinum toxin A is effective in treating trismus associated with postradiation myokymia and muscle spasm. Mov. Disord. (1995) 10(5):680-681.
   PubMed Web of Science ®Google Scholar
• VAN DAELE DJ, FINNEGAN EM, RODNITZKY RL et al.: Head and neck muscle spasm after radiotherapy: management with botulinum toxin A injection. Arch. Otolaryngol. Head Neck Surg. (2002) 128(8):956-959.
   PubMed Web of Science ®Google Scholar
• DE MICHELI C, FORNENGO P, BOSIO A et al.: Severe radiation-induced proctitis treated with botulinum anatoxin type A. J. Clin. Oncol. (2003) 21(13):2627.
   PubMed Web of Science ®Google Scholar
• LO NIGRO L, COSTANTINO F, SCHILIRO G: Safe administration of muscle-relaxing botulismotoxin during treatment for leukemia. Med. Pediatr. Oncol. (2002) 38(2):150.
   PubMedGoogle Scholar
• SENER EC, KIRATLI H, GEDIK S et al.: Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma. J. AAPOS (2004) 8(1):38-45.
   PubMed Web of Science ®Google Scholar
• ILHAN O, SENER EC, OZYAR E: Outcome of abducens nerve paralysis in patients with nasopharyngeal carcinoma. Eur. J. Ophthalmol. (2002) 12(1):55-59.
   PubMed Web of Science ®Google Scholar
• BIRCH JF, VARMA SK, NARULA AA: Botulinum toxoid in the management of gustatory sweating (Frey's syndrome) after superficial parotidectomy. Br. J. Plast. Surg. (1999) 52(3):230-231.
   PubMedGoogle Scholar
• KYRMIZAKIS DE, PANGALOS A, PAPADAKIS CE, LOGOTHETIS J, MAROUDIAS NJ, HELIDONIS ES: The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J. Oral Maxillofac. Surg. (2004) 62(7):840-844.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON LC, NEALE EA: Syntaxin and 25-kDa synaptosomal-associated protein: differential effects of botulinum neurotoxins C1 and A on neuronal survival. J. Neurosci. Res. (1998) 52(5):569-583.
   PubMed Web of Science ®Google Scholar
• IGARASHI M, KOZAKI S, TERAKAWA S, KAWANO S, IDE C, KOMIYA Y: Growth cone collapse and inhibition of neurite growth by Botulinum neurotoxin C1: a t-SNARE is involved in axonal growth. J. Cell Biol. (1996) 134(1):205-215.
   PubMed Web of Science ®Google Scholar
• SONVEAUX P, DESSY C, MARTINIVE P et al.: Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res. (2004) 64(9):3209-3214.
   PubMed Web of Science ®Google Scholar
• GALLEZ B, JORDAN BF, BAUDELET C, MISSON PD: Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry. Magn. Reson. Med. (1999) 42(4):627-630.
   PubMed Web of Science ®Google Scholar
• GALLEZ B, BAUDELET C, JORDAN BF: Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed. (2004) 17(5):240-262.
   PubMed Web of Science ®Google Scholar
• BAUDELET C, ANSIAUX R, JORDAN BF, HAVAUX X, MACQ B, GALLEZ B: Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys. Med. Biol. (2004) 49(15):3389-3411.
   PubMed Web of Science ®Google Scholar
• CRON GO, BEGHEIN N, ANSIAUX R, GALLEZ B: Botulinum toxin increases tumor uptake of gemcitabine chemotherapy as measured with fluorine spectroscopy. Proc. Intl. Soc. Mag. Reson. Med. (2006) 14:1764.
   Google Scholar
• KLEIN AW: Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol. Surg. (2003) 29(5):549-556.
   PubMed Web of Science ®Google Scholar
• VAN MELLAERT L, BARBE S, ANNE J: Clostridium spores as anti-tumour agents. Trends Microbiol. (2006) 14(4):190-196.
   PubMed Web of Science ®Google Scholar
• MINTON NP, MAUCHLINE ML, LEMMON MJ et al.: Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol. Rev. (1995) 17(3):357-364.
   PubMed Web of Science ®Google Scholar
• JORDAN BF, MISSON P, DEMEURE R, BAUDELET C, BEGHEIN N, GALLEZ B: Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int. J. Radiat. Oncol. Biol. Phys. (2000) 48(2):565-570.
   PubMed Web of Science ®Google Scholar
• ANSIAUX R, BAUDELET C, JORDAN BF et al.: Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. (2005) 11:743-750.
   PubMed Web of Science ®Google Scholar
• SEGERS J, FAZIO VD, ANSIAUX R et al.: Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett. (2006) 244:129-135.
   PubMed Web of Science ®Google Scholar
• BUSSINK J, KAANDERS JH, RIJKEN PF et al.: Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. Radiother. Oncol. (1999) 50(2):173-184.
   PubMed Web of Science ®Google Scholar
• BAUDELET C, GALLEZ B: How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn. Reson. Med. (2002) 48(6):980-986.
   PubMed Web of Science ®Google Scholar
• KLEINBERG L, GROSSMAN SA, CARSON K et al.: Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a Phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J. Clin. Oncol. (2002) 20(14):3149-3155.
   PubMed Web of Science ®Google Scholar
• HOU H, KHAN N, O'HARA JA et al.: Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: in vivo EPR oximetry study. Int. J. Radiat. Oncol. Biol. Phys. (2005) 61(5):1503-1509.
   PubMed Web of Science ®Google Scholar
• GODA F, BACIC G, O’HARA JA, GALLEZ B, SWARTZ HM, DUNN JF: The relationship between partial pressure of oxygen and perfusion in two murine tumors after X-ray irradiation: a combined gadopentetate dimeglumine dynamic magnetic resonance imaging and in vivo electron paramagnetic resonance oximetry study. Cancer Res. (1996) 56:3344-3349.
   PubMed Web of Science ®Google Scholar
• CROKART N, JORDAN BF, BAUDELET C et al.: Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int. J. Radiat. Oncol. Biol. Phys. (2005) 63(3):901-910.
   PubMed Web of Science ®Google Scholar
• CRON GO, BEGHEIN N, CROKART N et al.: Changes in the tumor microenvironment during low-dose-rate permanent seed implantation iodine-125 brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. (2005) 63(4):1245-1251.
   PubMed Web of Science ®Google Scholar
• BIAGLOW JE, MANEVICH Y, LEEPER D et al.: MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42(4):871-876.
   PubMed Web of Science ®Google Scholar
• JORDAN BF, GREGOIRE V, DEMEURE RJ et al.: Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res. (2002) 62(12):3555-3561.
   PubMed Web of Science ®Google Scholar
• CROKART N, RADERMACHER K, JORDAN BF et al.: Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res. (2005) 65(17):7911-7916.
   PubMed Web of Science ®Google Scholar
• CHADDOCK JA, MARKS PM: Clostridial neurotoxins: structure–function led design of new therapeutics. Cell. Mol. Life Sci. (2006) 63(5):540-551.
   PubMed Web of Science ®Google Scholar